Hüseyin Kaplan, Gizem Cengiz, Hasan Kara, İsa Cüce, Mehmet Kirnap, Mustafa Çaliş
{"title":"土耳其某参考中心风湿病实践中生物类似药处方率数据分析","authors":"Hüseyin Kaplan, Gizem Cengiz, Hasan Kara, İsa Cüce, Mehmet Kirnap, Mustafa Çaliş","doi":"10.1038/s41598-025-14816-0","DOIUrl":null,"url":null,"abstract":"<p><p>We aimed to determine the use/prescription rates of biosimilars (BSs) among patients being treated with biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). This retrospective study included 647 patients with axial spondyloarthritis (axSpA) and rheumatoid arthritis (RA). Patients' manual and electronic file records were reviewed and demographic, clinical, laboratory, and treatment-related data were collected. Details of the last prescribed and previously used b/tsDMARDs were noted. The data obtained were compared between groups according to disease type or BSs use. Logistic regression analysis was used to identify potential predictors associated with prescribing BSs. The mean age of all the patients was 48.1 ± 12.6 years, and 66% of the patients were women. The rate of BS use was 21.2% in all patients, and there was no significant difference in the rate of BS use between the axSpA and RA groups (22.2% vs. 19%; p = 0.337). The total duration of all b/tsDMARDs use was 4.3 (1-8.3) years in all patients. Although there was no difference between the patients with axSpA and RA in terms of total treatment duration with the last b/tsDMARD (p = 0.655), the total duration of all b/tsDMARDs use was significantly higher in patients with RA than in patients with axSpA (p = 0.001). The use of BSs increased with the number of treatment switches and prescription order(s) of b/tsDMARDs. The BSs prescription rate (39.7%) was highest in drugs prescribed as fifth order or later in patients with prior use of five or more distinct b/tsDMARDs. Female sex, disease duration, and the order of current b/tsDMARD were the most important predictors of preference for BSs over reference drugs. Approximately one in five patients were prescribed BSs among the patients being treated with b/tsDMARDs. The use/prescription rates of BSs were independent of disease type. In patients receiving two or more different b/tsDMARDs, the prescription rates for BSs tended to rise with later treatment line(s) relative to first-line b/tsDMARDs.</p>","PeriodicalId":21811,"journal":{"name":"Scientific Reports","volume":"15 1","pages":"28853"},"PeriodicalIF":3.9000,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12328602/pdf/","citationCount":"0","resultStr":"{\"title\":\"Analysis of data on biosimilar prescription rates in rheumatology practice from a reference center in Turkey.\",\"authors\":\"Hüseyin Kaplan, Gizem Cengiz, Hasan Kara, İsa Cüce, Mehmet Kirnap, Mustafa Çaliş\",\"doi\":\"10.1038/s41598-025-14816-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>We aimed to determine the use/prescription rates of biosimilars (BSs) among patients being treated with biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). This retrospective study included 647 patients with axial spondyloarthritis (axSpA) and rheumatoid arthritis (RA). Patients' manual and electronic file records were reviewed and demographic, clinical, laboratory, and treatment-related data were collected. Details of the last prescribed and previously used b/tsDMARDs were noted. The data obtained were compared between groups according to disease type or BSs use. Logistic regression analysis was used to identify potential predictors associated with prescribing BSs. The mean age of all the patients was 48.1 ± 12.6 years, and 66% of the patients were women. The rate of BS use was 21.2% in all patients, and there was no significant difference in the rate of BS use between the axSpA and RA groups (22.2% vs. 19%; p = 0.337). The total duration of all b/tsDMARDs use was 4.3 (1-8.3) years in all patients. Although there was no difference between the patients with axSpA and RA in terms of total treatment duration with the last b/tsDMARD (p = 0.655), the total duration of all b/tsDMARDs use was significantly higher in patients with RA than in patients with axSpA (p = 0.001). The use of BSs increased with the number of treatment switches and prescription order(s) of b/tsDMARDs. The BSs prescription rate (39.7%) was highest in drugs prescribed as fifth order or later in patients with prior use of five or more distinct b/tsDMARDs. Female sex, disease duration, and the order of current b/tsDMARD were the most important predictors of preference for BSs over reference drugs. Approximately one in five patients were prescribed BSs among the patients being treated with b/tsDMARDs. The use/prescription rates of BSs were independent of disease type. In patients receiving two or more different b/tsDMARDs, the prescription rates for BSs tended to rise with later treatment line(s) relative to first-line b/tsDMARDs.</p>\",\"PeriodicalId\":21811,\"journal\":{\"name\":\"Scientific Reports\",\"volume\":\"15 1\",\"pages\":\"28853\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-08-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12328602/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Scientific Reports\",\"FirstCategoryId\":\"103\",\"ListUrlMain\":\"https://doi.org/10.1038/s41598-025-14816-0\",\"RegionNum\":2,\"RegionCategory\":\"综合性期刊\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MULTIDISCIPLINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scientific Reports","FirstCategoryId":"103","ListUrlMain":"https://doi.org/10.1038/s41598-025-14816-0","RegionNum":2,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
Analysis of data on biosimilar prescription rates in rheumatology practice from a reference center in Turkey.
We aimed to determine the use/prescription rates of biosimilars (BSs) among patients being treated with biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). This retrospective study included 647 patients with axial spondyloarthritis (axSpA) and rheumatoid arthritis (RA). Patients' manual and electronic file records were reviewed and demographic, clinical, laboratory, and treatment-related data were collected. Details of the last prescribed and previously used b/tsDMARDs were noted. The data obtained were compared between groups according to disease type or BSs use. Logistic regression analysis was used to identify potential predictors associated with prescribing BSs. The mean age of all the patients was 48.1 ± 12.6 years, and 66% of the patients were women. The rate of BS use was 21.2% in all patients, and there was no significant difference in the rate of BS use between the axSpA and RA groups (22.2% vs. 19%; p = 0.337). The total duration of all b/tsDMARDs use was 4.3 (1-8.3) years in all patients. Although there was no difference between the patients with axSpA and RA in terms of total treatment duration with the last b/tsDMARD (p = 0.655), the total duration of all b/tsDMARDs use was significantly higher in patients with RA than in patients with axSpA (p = 0.001). The use of BSs increased with the number of treatment switches and prescription order(s) of b/tsDMARDs. The BSs prescription rate (39.7%) was highest in drugs prescribed as fifth order or later in patients with prior use of five or more distinct b/tsDMARDs. Female sex, disease duration, and the order of current b/tsDMARD were the most important predictors of preference for BSs over reference drugs. Approximately one in five patients were prescribed BSs among the patients being treated with b/tsDMARDs. The use/prescription rates of BSs were independent of disease type. In patients receiving two or more different b/tsDMARDs, the prescription rates for BSs tended to rise with later treatment line(s) relative to first-line b/tsDMARDs.
期刊介绍：
We publish original research from all areas of the natural sciences, psychology, medicine and engineering. You can learn more about what we publish by browsing our specific scientific subject areas below or explore Scientific Reports by browsing all articles and collections.
Scientific Reports has a 2-year impact factor: 4.380 (2021), and is the 6th most-cited journal in the world, with more than 540,000 citations in 2020 (Clarivate Analytics, 2021).
•Engineering
Engineering covers all aspects of engineering, technology, and applied science. It plays a crucial role in the development of technologies to address some of the world''s biggest challenges, helping to save lives and improve the way we live.
•Physical sciences
Physical sciences are those academic disciplines that aim to uncover the underlying laws of nature — often written in the language of mathematics. It is a collective term for areas of study including astronomy, chemistry, materials science and physics.
•Earth and environmental sciences
Earth and environmental sciences cover all aspects of Earth and planetary science and broadly encompass solid Earth processes, surface and atmospheric dynamics, Earth system history, climate and climate change, marine and freshwater systems, and ecology. It also considers the interactions between humans and these systems.
•Biological sciences
Biological sciences encompass all the divisions of natural sciences examining various aspects of vital processes. The concept includes anatomy, physiology, cell biology, biochemistry and biophysics, and covers all organisms from microorganisms, animals to plants.
•Health sciences
The health sciences study health, disease and healthcare. This field of study aims to develop knowledge, interventions and technology for use in healthcare to improve the treatment of patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
